This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain

This study has been completed.
Information provided by:
University of Manitoba Identifier:
First received: February 10, 2006
Last updated: July 26, 2012
Last verified: March 2011
This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.

Condition Intervention Phase
Neuropathic Pain Multiple Sclerosis Drug: paroxetine Drug: pregabalin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine

Resource links provided by NLM:

Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Pain levels (as determined by weekly Visual Analogue Scale for pain) [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Short-Form 36 health outcomes survey (SF-36) [ Time Frame: 8 weeks ]
  • Short-form McGill Pain Questionnaire (SF MPQ) [ Time Frame: 8 weeks ]
  • Patient-rated Global Impression of Change (PGIC) [ Time Frame: 8 weeks ]

Estimated Enrollment: 75
Study Start Date: March 2006
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Paroxetine Drug: paroxetine
Active Comparator: pregabalin Drug: pregabalin

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • • Patients presenting with symptoms of neuropathic pain as determined by clinician, with a minimum VAS pain score of 40mm as determined by a baseline score (0mm = no pain, 100mm = worst pain).

    • Male and female patients between the ages of 18 and 65 years old.
    • Clinically definite multiple sclerosis as defined by clinical history review, neurological examination and positive MRI.
    • EDSS scores of < 6.0.
    • No known hypersensitivity to the study medications.
    • Negative serum pregnancy test for all female patients of childbearing age; not currently breastfeeding.
    • Not currently treated with pregabalin, gabapentin, paroxetine or another SSRI.
    • No previous treatment failures with pregabalin or paroxetine.
    • Baseline creatinine clearance (Clcr) of > 50mL/min.
    • No significant hepatic insufficiency.
    • If on other pain medications, must be on stable dose for at least 6 months and other medications must not elicit significant drug-drug interactions with study medications.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00291148

Canada, Manitoba
Multiple Sclerosis Clinic, Health Sciences Centre
Winnipeg, Manitoba, Canada, R3T 2N2
Sponsors and Collaborators
University of Manitoba
Principal Investigator: Micheal P Namaka, PhD University of Manitoba
Principal Investigator: Dana A Turcotte, BSc Pharm University of Manitoba
  More Information Identifier: NCT00291148     History of Changes
Other Study ID Numbers: MS_B2005:168
Study First Received: February 10, 2006
Last Updated: July 26, 2012

Keywords provided by University of Manitoba:
Neuropathic pain
Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Neurologic Manifestations
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors processed this record on August 18, 2017